Business
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients Additional
About this update from Crinetics Pharmaceuticals, Inc.
[{"type":"text","content":"New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients Additional Research Includes Acromegaly Symptom Burden and Standard-of-Care Discontinuation Rates SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15–17 in Orlando, FL. One presentation is a post-hoc analysis showing investigational candidate paltusotine provided rapid and durable treatment effects and was well tolerated in surgically naïve patients with acromegaly. The second presentation on symptom variability in acromegaly shows the significant disease burden that patients on long-acting injectable somatostatin analogs can experience. Additionally, one other acromegaly abstract – a real-world evidence analysis revealing high discontinuation rates with the existing standard-of-care treatment – and one abstract on investigational candidate atumelnant will be included in an AACE supplemental journal publication following the meeting. The atumelnant abstract features new data from a Phase 1b/2a study that provides insights into hydrocortisone administration and cortisol monitoring in patients with adrenocorticotropic hormone (ACTH)-dependent Cushing’s syndrome. “We believe our lead development candidate, paltusotine, has the potential to deliver meaningful improvements for people living with acromegaly, and are encouraged by recent progress in both the U.S. and EU where regulatory reviews of its proposed use remain on track,” said Dana Pizzuti, M.D., Chief Medical and Development Officer, Crinetics. “As we prepare for a PDUFA action date of September 25 in the U.S., the research we’re presenting and publishing at AACE this year reinforces the potential for this novel, once-daily oral medicine, if approved, to advance the standard of care for people living with acromegaly.” In addition to scientific presentations and publications, Crinetics is also sponsoring a Product Theater titled “Navigating the Complexities & Challenges of Acromegaly Management” featuring expert insights from: Dr. Elena Christofides, Chief Executive Officer, Endocrinology Associates, Inc.; Dr. Leena Shahla, Medical Director, Duke Un...